CLOs on the Move

Marina Biotech

www.marinabio.com

 
Marina Biotech`s focus is to treat the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company`s `next-generation of celecoxib,` including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combating the opioid epidemic. They are also being developed as anticancer agents against FAP and CRC. On the Sales and Marketing front- we are actively promoting sales and distribution of our ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.marinabio.com
  • 17870 Castleton Street Ste. 250
    City of Industry, CA USA 91748
  • Phone: 626.964.5788

Executives

Name Title Contact Details

Similar Companies

Alta Biomedical Group

Alta Biomedical Group is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Provident Clinical Research and Consulting

Provident Clinical Research & Consulting, Inc. is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

NPS Pharmaceuticals

NPS Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

StrideBio

StrideBio is a product-driven, fully integrated gene therapy company focused on creating and developing innovative genetic medicines with life-changing or curative potential for patients with devastating conditions, including monogenic rare disease and beyond. We leverage our proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Improved characteristics of StrideBio`s AAV vectors include evasion of pre-existing neutralizing antibodies, tissue targeting and de-targeting, enhanced potency, and manufacturability at scale. Combined with our gene construct design expertise and in-house manufacturing capabilities, StrideBio is positioned to generate best-in-class genetic medicines that allow more patients to benefit with maximum efficiency. StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C, which houses our offices, research labs and in-house AAV manufacturing facilities.

Capital Royalty L.P.

Capital Royalty L.P. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.